Pacira Pharmaceuticals (PCRX) Posts Q4 Loss of 72c/Share

Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q4 EPS of ($0.72), $0.18 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $4.23 million versus the consensus estimate of $4.05 million.

For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c